ClinicalTrials.gg
RecruitingNCT07691606ABLATE-101Updated Nov 2, 2026

A Study of ARC-02 in B-cell NHL

A Phase 1 interventional study of ARC-02 and Rituximab in B-cell Non Hodgkin Lymphoma, sponsored by Taiho Oncology, Inc.. Recruiting at 28 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 2, 2026Site recruiting status changed1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 399 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Planned enrollment
58th of 381
140 · median 37
Started
2026
with 20 others
Phase 1
162 of 399
35 open now
Primary completion
2029-01
later than 121 of 156 live
Registered
394th of 399
by date

Among the 399 studies in Lymphoma, B-Cell with a site in United States, this one is the 58th largest by planned enrollment of the 381 interventional ones that give a count, is one of 21 that started in 2026, is one of 162 in phase 1, reaches primary completion later than 121 of the 156 other live ones, and was the 394th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

91 of the 399 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

85 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 208 Lymphoma, B-Cell studies recruiting now, 128 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 399 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.

03

Conditions studied

  • B-cell Non Hodgkin Lymphoma

Keywords

  • Non-Hodgkin's Lymphomas
  • Diffuse Large B-Cell Lymphoma
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Waldenstroms Macroglobulinemia
  • Germinal Center B-cell
  • Activated B-Cell
  • NHL
  • DLBCL
  • MCL
  • FL
  • MZL
  • WM
  • GCB
  • ABC
  • Cancer
  • ARC-02
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A documented diagnosis of B-cell Non- Hodgkin Lymphoma (NHL) per 2016 World Health Organization criteria and disease requiring treatment:

    1. Follicular lymphoma (FL), Grades 1 through 3B
    2. Marginal zone lymphoma (MZL)
    3. Mantle cell lymphoma (MCL)
    4. Diffuse large B-cell lymphoma (DLBCL)
    5. Other B-cell NHL
  2. .
  3. Received at least 2 and not eligible to receive additional standard of care therapies.
  4. An Performance Status (ECOG PS) ≤ 2 at screening.
  5. Adequate organ function within 3 days of the first dose of study intervention.
  6. A negative blood pregnancy test within 7 days prior to first dose of study intervention (for women of ).

Exclusion criteria

Exclusion Criteria:

  1. Receiving an product or participating in any other type of medical research judged not to be compatible with this study.
  2. Grade > 1 neuropathy
  3. History of interstitial lung disease (ILD)/pneumonitis requiring treatment or any evidence of active ILD/pneumonitis.
  4. Use of:

    1. Chemotherapy, radiotherapy, small molecule, investigational, and biologic agents (including CD79b-directed agents) within 28 days (or at least 5 half-lives, whichever is shorter), prior to the first dose of the study intervention.
    2. Any live or within 28 days before the first dose of the study intervention.
  5. Ongoing toxicity from prior anticancer therapy that has not resolved to Grade ≤ 2 (neutropenia) or Grade ≤ 1 (thrombocytopenia or nonhematologic toxicities), with the exception of alopecia.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Part A Dose Escalation: ARC-02 Monotherapy

    Participants will receive ARC-02 at multiple dose levels on Day 1 of each cycle until disease progression or unacceptable toxicity.

    Drug: ARC-02

  • Experimental
    Part A Dose Expansion: ARC-02 Monotherapy

    Participants will receive ARC-02 at a dose determined in Part A Dose Escalation on Day 1 of each cycle until disease progression or unacceptable toxicity.

    Drug: ARC-02

  • Experimental
    Part B Dose Escalation: ARC-02 in Combination with Rituximab

    Participants will receive ARC-02 at multiple dose levels on Day 1 of each cycle at multiple dose levels in combination with rituximab until disease progression or unacceptable toxicity.

    Drug: ARC-02 · Drug: Rituximab

  • Experimental
    Part B Dose Expansion: ARC-02 in Combination with Rituximab

    Participants will receive ARC-02 at a dose determined in Part B Dose Escalation on Day 1 of each cycle in combination with rituximab until disease progression or unacceptable toxicity.

    Drug: ARC-02 · Drug: Rituximab

Interventions

  • DrugARC-02

    Intravenous (IV) infusion.

  • IV infusion.

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Number of Participants with Dose-Limiting Toxicities (DLTs)

    Time frame: Up to 5 years

  2. Dose Escalation: Number of Participants with Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 5 years

  3. Dose Expansion: Objective Response Rate (ORR) as Assessed by the Investigator

    Time frame: Up to 5 years

Secondary outcomes

  1. Dose Escalation: ORR as Assessed by the Investigator

    Time frame: Up to 5 years

  2. Dose Expansion: Number of Participants with TEAEs and SAEs

    Time frame: Up to 5 years

  3. Dose Escalation and Expansion: Time to Response (TTR)

    Time frame: Up to 5 years

  4. Dose Escalation and Expansion: Duration of Response (DOR)

    Time frame: Up to 5 years

  5. Dose Escalation and Expansion: Progression-free Survival (PFS)

    Time frame: Up to 5 years

  6. Dose Escalation and Expansion: Maximum Observed Plasma Concentration (Cmax)

    This will be assessed for antibody conjugated monomethyl auristatin E (acMMAE), total anti-CD79b antibody and free monomethyl auristatin E (MMAE).

    Time frame: Up to 5 years

  7. Dose Escalation and Expansion: Apparent Elimination Half-Life (t½)

    This will be assessed for acMMAE, total anti-CD79b antibody and free MMAE.

    Time frame: Up to 5 years

  8. Dose Escalation and Expansion: AUC From Time 0 to Infinity (AUC0-inf)

    This will be assessed for acMMAE, total anti-CD79b antibody and free MMAE.

    Time frame: Up to 5 years

  9. Dose Escalation and Expansion: AUC to the Last Measurable Concentration (AUC(0-τ)

    This will be assessed for acMMAE, total anti-CD79b antibody and free MMAE.

    Time frame: Up to 5 years

  10. Dose Escalation and Expansion: Number of Participants with Antidrug Antibodies (ADA) and Neutralizing Antibodies (Nab)

    Time frame: Up to 5 years

07

Study locations

3 of 28 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2029, 31 months after the start.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 31 months is below that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 9, 2026
StartActual
Jun 22, 2026
Primary completionEst.
Jan 2029
CompletionEst.
Dec 2030
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed. Linear Clinical Research is now Recruiting
Show 1 removed
  • NYU Langone · New York, United States
across 2 updates, Oct 8, 2026 – Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    1 site removed
    Show 1 removed
    • NYU Langone · New York, United States
  2. Oct 8, 2026
    Linear Clinical Research is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07691606
Responsible party
Sponsor
First posted
Jul 9, 2026
Start date
Jun 22, 2026
Primary completion
Jan 2029 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 2, 2026

Study contacts

Taiho Oncology, Inc.
Contact
medicalinformation@taihooncology.com
+1 844-878-2446

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion